Xinrong Medical | Top Orthopedic Solutions Company in APAC 2021

MedTech Outlook Magazine

Xinrong Medical
Introducing Cutting-Edge, Comprehensive Solutions in China's Orthopedic Market

Christine Zhang, CEO, Xinrong MedicalChristine Zhang, CEO
"Founded in 2000, Xinrong Medical, after 21 years of development, has become one of the leading manufacturers of orthopedic implant consumables for limb trauma, spine and joint injury in China," says Christine Zhang, CEO of Xinrong Medical, "It is also the first medical device manufacturer that has passed the simulation pilot inspection of the quality management system (GMP) for implantable medical device manufacturers in China."

Xinrong Medical is a professional orthopedic implant manufacturer invested by The Blackstone Group (NYSE: BX), a leading global investment institution. It is a leading enterprise in orthopedic implants and complementary products in China and the earliest company in China with a full range of high-quality product lines that cover joints, trauma, and the spinal column. Its products include hip joint prosthesis system series, spinal internal fixator series, interlocking intramedullary nail series, threaded plate screw series, nickel-titanium memory alloy embracing fixator series, and metal bone plate, nails, needles, and other series of products.

Currently, Xinrong Medical is moving forward with new materials, new technologies, and minimally invasive therapy. With the third market share in the domestic trauma space and the seventh market share in the domestic spine field, Xinrong Medical has emerged as a leading orthopedic implant manufacturing enterprise in China. The company is also one of the high-tech enterprises in Jiangsu Province and has been certified by the ISO9001, ISO13485 Quality Systems, and CE.

Leveraging the strong international resources of Blackstone Group, Xinrong Medical has established an international management team to ensure the company's efficient operation.
It has created a comprehensive orthopedic agency platform, a research and development team, advanced production and processing & quality control system, and Xinrong Medical College to provide training and education at the level of multinational enterprises for doctors in China. With a prominent presence in sales channels of county-level hospitals in China, combined with an innovative strategy, Xinrong Medical covers more than 3,000 hospitals and has become the leader of China's grass-roots hospitals.

Based on the data of Chinese bone anatomy, Xinrong Medical has developed several expert intramedullary nail systems. These can be used in fractures in the humerus, femur, tibia, fibula, and other parts. It adopts the micron level gauge for controlling machining precision such that the intramedullary nail system has high accuracy, and nail surgery is done with minimal invasion. The superior clinical performance of Xinrong's expert-level intramedullary nail system has also won a good reputation in the industry. "Since 2019, the products of Xinrong Medical have acquired high recognition from the Global Big Four Orthopedic Company," adds Zhang.

  • Xinrong Medical is a professional orthopedic implant manufacturer invested by The Blackstone Group (NYSE: BX), a leading global investment institution.


As for Xinrong Medical's plans, Zhang says that there are three aspects that the team is currently working towards. Firstly, regarding the introduction of new materials, the team at Xinrong Medical is working to develop HA-PEEK spine cages, PEEK lock plates, and biodegradable implants, such as cervical spine cages and non-load-bearing fracture implants. Next, the company aims to create a 3D-printed customized prosthesis in line with the knee's anatomy and motor function. Xinrong Medical plans to partner with Conformis Company in the United States to develop this customized knee prosthesis. Thirdly, Xinrong aims to create an orthopedic robot for joint replacement. The team is looking into a partnership with SpineGuard to develop Smart Screw, a spinal Screw with spinal navigation function. The mission objective at Xinrong Medical is to make an overall foray into the field of the orthopedic industry with a full range of spine, joint, and trauma products.

Top 10 Orthopedic Solutions Companies in APAC - 2021

Company
Xinrong Medical

Management
Christine Zhang, CEO

Description
A leading orthopedic enterprise in China, with compliance and quality first, standardized management and industry-leading technology. Leveraging the strong international resources of Blackstone Group, Xinrong Medical has established an international management team to ensure the efficient operation of the company. It has created a comprehensive orthopedic agency platform, a research and development team, advanced production and processing & quality control system, and Xinrong Medical College to provide training and education at the level of multinational enterprises for doctors in China. Quote: It is the first medical device manufacturer that has passed the simulation pilot inspection of the quality management system (GMP) for implantable medical device manufacturers in China

Xinrong Medical News

XinRong Medical places a large purchase order of PediGuard devices and invests in SpineGuard to boost DSG technology's deployment in China

PARIS & BOULDER, Colo: SpineGuard (FR0011464452 – ALSGD), an innovative company that deploys its DSG (Dynamic Surgical Guidance) sensing technology to secure and streamline the insertion of bone implants, and XinRong Medical Group, a China leader in medical technology, announced today the placement of a large purchase order of PediGuard devices and the completion of a capital increase primarily intended to fund the registration of the whole SpineGuard product portfolio by the Chinese NMPA (National Medical Product Administration).
Following the announcement of the extended distribution agreement on May 16, XinRong Medical has placed an order for 448 Straight PediGuard units. Additionally, SpineGuard, in collaboration with XinRong's input, has appointed a third-party regulatory agent to facilitate the Chinese registration process for other versions of PediGuard, including the Curved, XS, Canulated, and Threaded spinal drilling probes, all incorporating SpineGuard's DSG (Dynamic Surgical Guidance) technology.
As part of the agreement terms revealed on May 16, XinRong Medical has fulfilled its equity contribution to SpineGuard through the following actions:
● Issuance of 500,000 new SpineGuard shares
● Share price set at €1.00 per share
● A total equity injection of €500K by XinRong Medical
● This contribution represents 1.28% of the currently issued shares
● The equity shares will be under a lock-up period of 18 months.
The spine market in China ranks as the second-largest globally, only after the USA. This growth is driven by an aging population, increasing disease prevalence, higher treatment rates, and improved access to care, which has enhanced affordability in the country.
Pierre Jérôme, Chairman, CEO and Co-founder of SpineGuard, said: “I am delighted that our recently signed three-prong agreement with XinRong is swiftly materializing. This € 500,000 cash injection will finance the regulatory approval of the whole PediGuard product range in China. It confirms XinRong’s ambition and commitment to mobilize the necessary means for properly deploying SpineGuard’s DSG technology in the largest market for spinal surgical devices after the United States. This equity stake strengthens our collaboration and further aligns both companies’ interests which I believe is essential to make such partnership successful.”
Christine Zhang, CEO of XinRong Medical, added: “I am thrilled about our partnership with SpineGuard. Our investment in the company represents our shared commitment to innovation and advancing medical technology. We believe that SpineGuard's DSG technology will revolutionize spinal surgical devices and we are excited to be a part of that journey. The completion of this capital increase reinforces our dedication to bringing the latest medical advancements to patients in China and beyond. We look forward to working closely with SpineGuard over the coming years and are confident that our collaboration will yield significant results.”
“PediGuard increases safety for better screw placement, reduces surgical time, decreases X-ray exposure for patients, surgeons and staff and also helps train the young surgeons. It is a very useful and convenient device that is effective without any other supplementary equipment for complex spine surgery, especially for spinal deformity cases.” said Professor Yong Qiu, Chairman of Orthopedic Surgery of Nanjing Drum Tower Hospital and President of the Chinese Scoliosis Research Society.
Professor Weishi Li, Chief of Department of Orthopedics of Peking University Third Hospital (PKUTH), and Chairman of the AO Spine China Council, concluded: “As a medical expert, I would like to extend my heartfelt congratulations to SpineGuard and XinRong Medical Group on their new partnership. The placement of a large purchase order of PediGuard devices and the completion of a capital increase to fund the registration of the whole SpineGuard product portfolio by the Chinese NMPA is a significant achievement. I am excited about the potential impact that SpineGuard's DSG technology will have on spinal surgical devices in China, which is the world's second-largest market after the USA. The benefits of PediGuard in terms of increased safety, reduced surgical time, and decreased X-ray exposure are well-known, and I look forward to seeing this innovative technology being used to improve patient outcomes in China. Congratulations again to both companies on this exciting partnership.”